EP4704833A2 - Sels d'amines quaternaires d'alcoxy et de carbamoyle utilisés comme promédicaments de trpytamines - Google Patents

Sels d'amines quaternaires d'alcoxy et de carbamoyle utilisés comme promédicaments de trpytamines

Info

Publication number
EP4704833A2
EP4704833A2 EP24798171.5A EP24798171A EP4704833A2 EP 4704833 A2 EP4704833 A2 EP 4704833A2 EP 24798171 A EP24798171 A EP 24798171A EP 4704833 A2 EP4704833 A2 EP 4704833A2
Authority
EP
European Patent Office
Prior art keywords
compound
disorder
minutes
cycloalkyl
life
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24798171.5A
Other languages
German (de)
English (en)
Inventor
Alan Gibbs
Tanweer Khan
Bob PERNI
Glenn Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atai Therapeutics Inc
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of EP4704833A2 publication Critical patent/EP4704833A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés pharmaceutiques montrant un potentiel pour le traitement de troubles de la santé mentale, lesquels composés surmontent les problèmes de solubilité et de biodisponibilité orale pour jouer le rôle d'agonistes (partiels) du récepteur de la sérotonine du SNC, 5-HT2A.
EP24798171.5A 2023-04-27 2024-04-29 Sels d'amines quaternaires d'alcoxy et de carbamoyle utilisés comme promédicaments de trpytamines Pending EP4704833A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363576462P 2023-04-27 2023-04-27
PCT/US2024/026797 WO2024227149A2 (fr) 2023-04-27 2024-04-29 Sels d'amines quaternaires d'alcoxy et de carbamoyle utilisés comme promédicaments de trpytamines

Publications (1)

Publication Number Publication Date
EP4704833A2 true EP4704833A2 (fr) 2026-03-11

Family

ID=93257462

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24798171.5A Pending EP4704833A2 (fr) 2023-04-27 2024-04-29 Sels d'amines quaternaires d'alcoxy et de carbamoyle utilisés comme promédicaments de trpytamines

Country Status (2)

Country Link
EP (1) EP4704833A2 (fr)
WO (1) WO2024227149A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021226416A1 (fr) 2020-05-08 2021-11-11 Psilera Inc. Nouvelles compositions de matière et compositions pharmaceutiques
CA3218110A1 (fr) 2021-05-25 2022-12-01 Majed Fawaz Nouveaux sels de n,n-dimethyltryptamine et nouvelles formes de sel cristallin
WO2023129956A2 (fr) 2021-12-30 2023-07-06 ATAI Life Sciences AG Analogues de diméthyltryptamine utilisés en tant que médicaments d'administration d'oxyde nitrique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220137081A (ko) * 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
AU2022206448B2 (en) * 2021-01-11 2024-04-18 Caamtech, Inc. Quaternary tryptamines and their therapeutic uses
AU2022287974A1 (en) * 2021-06-09 2024-01-04 Atai Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine
EP4137131A1 (fr) * 2021-08-17 2023-02-22 Centre National de la Recherche Scientifique (CNRS) Nouveaux analogues de sérotonine et leurs utilisations pour le traitement des troubles associés au fer
WO2024118767A2 (fr) * 2022-11-29 2024-06-06 Caamtech, Inc. Dérivés de tryptamine

Also Published As

Publication number Publication date
WO2024227149A2 (fr) 2024-10-31
WO2024227149A3 (fr) 2025-02-06

Similar Documents

Publication Publication Date Title
EP4704833A2 (fr) Sels d'amines quaternaires d'alcoxy et de carbamoyle utilisés comme promédicaments de trpytamines
CN111818918B (zh) 用于治疗囊性纤维化的药物组合物
CA2744708C (fr) Agents induisant l'apoptose pour le traitement du cancer et de maladies immunes et auto-immunes
TWI537269B (zh) 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘發劑
JP5852666B2 (ja) １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
WO2019191620A1 (fr) Formes cristallines de modulateurs de cftr
CN115884971A (zh) 取代的哌啶化合物及其用途
EP3508481A1 (fr) Forme cristalline du chlorhydrate de l'ozanimod et son procédé de préparation
TW201200511A (en) Crystalline salts of a potent HCV inhibitor
CN110088092A (zh) 化合物，获得化合物的方法，药物组合物，化合物的用途和治疗精神障碍和/或睡眠障碍的方法
AU2019265011B2 (en) Inhibitors of the RAS oncoprotein, methods of making and methods of use thereof
CN113549073B (zh) 作为JAK抑制剂的吡唑并[1,5-a]嘧啶衍生物
CN103360342A (zh) 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
JP7628252B2 (ja) 二環式ピリジン組成物およびがんの治療にそれを使用する方法
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
CN100569740C (zh) N-or酰胺类化合物,其制备方法和其应用
CA3176727A1 (fr) Composes antiviraux de 1,3-di-oxo-indene
WO2021184958A1 (fr) Inhibiteur de l'angiogenèse, son procédé de préparation et son utilisation
CN120424027B (zh) 一种伏硫西汀半帕莫酸盐晶型
EP3781568A1 (fr) Forme de ponatinib
TW202104216A (zh) Plk4抑制劑之結晶型
CN116120254B (zh) 13,14-双一氧化氮供体-β-榄香烯衍生物及其制备和应用
CN112759583B (zh) 包含呋喃基的喹啉类衍生物及其制备方法和用途
CN103772374B (zh) 一种杂环类化合物及其应用
CN103127520A (zh) 聚乙二醇与坦索罗辛的结合物及其药物组合物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251027

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR